|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 19.75 AUD | 0.00% |
|
+0.56% | +58.00% |
| Capitalization | 2.5B 1.66B 1.43B 1.34B 1.24B 2.3B 149B 15.62B 6.03B 70.5B 6.23B 6.09B 258B | P/E ratio 2025 * |
142x | P/E ratio 2026 * | 51.3x |
|---|---|---|---|---|---|
| Enterprise value | 2.18B 1.44B 1.24B 1.16B 1.08B 2B 130B 13.6B 5.25B 61.37B 5.42B 5.3B 224B | EV / Sales 2025 * |
33.3x | EV / Sales 2026 * | 15.5x |
| Free-Float |
83.48% | Yield 2025 * |
-
| Yield 2026 * | 0.63% |
Last Transcript: Neuren Pharmaceuticals Limited
| 1 week | +0.56% | ||
| Current month | +0.56% | ||
| 1 month | +6.30% | ||
| 3 months | -3.56% | ||
| 6 months | +43.53% | ||
| Current year | +58.00% |
| 1 week | 18.82 |  | 20.11 |
| 1 month | 18.01 | | 20.11 |
| Current year | 8.61 | | 22.98 |
| 1 year | 8.61 | | 22.98 |
| 3 years | 6.72 | | 25.95 |
| 5 years | 1.2 | | 25.95 |
| 10 years | 0.82 | | 25.95 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jon Pilcher
CEO | Chief Executive Officer | 59 | 27/05/2020 |
Lauren Frazer
DFI | Director of Finance/CFO | - | 01/08/2020 |
Liza Squires
CTO | Chief Tech/Sci/R&D Officer | - | 08/07/2022 |
| Director | Title | Age | Since |
|---|---|---|---|
Jon Pilcher
BRD | Director/Board Member | 59 | 14/06/2021 |
Dianne Angus
BRD | Director/Board Member | 64 | 05/07/2018 |
Patrick Davies
CHM | Chairman | 58 | 27/05/2020 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 0.00% | +0.56% | +54.30% | +169.07% | 1.66B | |
| -1.48% | -6.25% | +23.42% | +166.75% | 905B | |
| +0.43% | -1.28% | +35.51% | +14.40% | 487B | |
| -0.41% | +0.10% | +27.62% | +35.75% | 400B | |
| +2.19% | +2.65% | +23.33% | +4.70% | 330B | |
| -0.43% | -2.21% | +26.42% | +19.57% | 281B | |
| -0.49% | +2.21% | +19.22% | +24.92% | 255B | |
| -0.68% | -3.23% | -5.05% | -11.10% | 248B | |
| -3.21% | -4.82% | -61.74% | -33.29% | 214B | |
| -1.78% | -4.03% | +16.66% | +13.42% | 178B | |
| Average | -0.67% | -1.94% | +15.97% | +40.42% | 329.82B | |
| Weighted average by Cap. | -0.69% | -2.79% | +17.61% | +54.07% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 65.43M 43.39M 37.3M 34.94M 32.57M 60.16M 3.91B 409M 158M 1.84B 163M 159M 6.74B | 137M 90.78M 78.04M 73.1M 68.14M 126M 8.17B 855M 330M 3.86B 341M 333M 14.11B |
| Net income | 17.59M 11.66M 10.02M 9.39M 8.75M 16.17M 1.05B 110M 42.41M 496M 43.77M 42.84M 1.81B | 48.04M 31.86M 27.38M 25.65M 23.91M 44.16M 2.87B 300M 116M 1.35B 120M 117M 4.95B |
| Net Debt | -324M -215M -185M -173M -161M -298M -19.33B -2.02B -781M -9.13B -806M -789M -33.38B | -373M -247M -212M -199M -185M -343M -22.24B -2.33B -899M -10.5B -927M -908M -38.41B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 08/12/25 | 19.75 $ | 0.00% | 242,947 |
| 05/12/25 | 19.75 $ | +3.51% | 200,947 |
| 04/12/25 | 19.08 $ | -0.26% | 174,911 |
| 03/12/25 | 19.13 $ | +0.26% | 254,341 |
| 02/12/25 | 19.08 $ | -0.68% | 312,160 |
Delayed Quote Australian S.E., 08 December 2025 at 04:10 pm AEDT
More quotes
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- NEU Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition